Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration

CompletedOBSERVATIONAL
Enrollment

650

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
C10.114.375.500
Interventions
OTHER

Delay between MS onset and introduction of first line DMT

Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)

OTHER

EDI

For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.

Trial Locations (4)

14033

University Hospital Center of Caen, Caen

59020

Groupement des Hôpitaux de l'Institut Catholique de Lille (HICL), Lille

59037

University Hospital of Lille, Lille

76031

University Hospital of Rouen, Rouen

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

collaborator

Ligue contre le cancer, France

OTHER

lead

University Hospital, Caen

OTHER

NCT03308994 - Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration | Biotech Hunter | Biotech Hunter